Dyslipidemia observed in ESRD is characterized by the hypertriglyceridemia, increase in IDL-C and chylomicron remnants, and a reduction in HDL-C and apolipoprotein (apo) AI (apoA-I) as well as apoC-II/apoC-III ratio [33,34]. The gene discussed is APOA1; the disease is metabolic syndrome.